Crossmark

[Translated article] Real-World Evidence of Adjuvant Immunotherapy in Resected Stage III and IV Melanoma Patients: CADIM Trial Final Results. Experience From 2 Tertiary Referral Centers

Crossref DOI link: https://doi.org/10.1016/j.ad.2024.12.008

Published Print: 2025-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Morellá Fernández, M.

Balsalobre Yago, J.

Martínez García, J.

Peláez Gutiérrez, M.

López Muñoz, A.

Silvestre Ballesta, A.I.

Sánchez Lafuente, B.

Martínez Martín, I.

Cerezuela Fuentes, P.
License Information

Text and Data Mining valid from 2025-03-01

Text and Data Mining valid from 2025-03-01

Version of Record valid from 2024-12-22
More Information

This article is maintained by: Elsevier

Article Title: [Translated article] Real-World Evidence of Adjuvant Immunotherapy in Resected Stage III and IV Melanoma Patients: CADIM Trial Final Results. Experience From 2 Tertiary Referral Centers

Journal Title: Actas Dermo-Sifiliográficas

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ad.2024.12.008

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.ad.2024.07.021

Content Type: article

Copyright: © 2024 AEDV. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below